HANEFİ ÖZBEK, Mustafa KÖSEM, ENDER ERDOĞAN, İrfan BAYRAM, Ahmet DURMUŞ, İmdat DİLEK

Karboplatine bağlı organ toksisitelerinde pentoksifilin, C vitamini ve E vitamininin etkisi

Bu çalışmada antineoplastik bir ajan olan karboplatinin sıçanlarda çeşitli organ ve dokular üzerindeki toksisitesi üzerine pentoksifilin (PTX), C ve E vitamininin koruyucu etkileri karşılaştırmalı olarak araştırıldı. Otuz adet sıçan, beş çalışma grubuna (n=6) ayrıldı: Grup I; 0.2 mL serum fizyolojik, grup II; 25 mg/kg karboplatin, Grup III; 25 mg/kg karboplatin + 150 mg/kg pentoksifilin, Grup IV; 25 mg/kg karboplatin + 50 mg/kg C vitamini ve Grup V; 25 mg/kg karboplatin + 50 mg/kg E vitamini intraperitoneal (ip) yolla beş gün süreyle alacak şekilde düzenlendi. Çalışmanın sonunda sıçan serumlarında ALT, ALP, direkt ve indirekt bilirubin seviyelerine bakıldı. Dokular standart histopatolojik yöntemlerle incelendi. Çalışma sonunda histopatolojik yönden karboplatin grubuna ait herhangi bir patolojik bulguya rastlanmazken, serum ALP ve ALT değerlerinin kontrol grubuna göre anlamlı derecede yükseldiği gözlendi. PTX, C ve E vitamini gruplarında ise yine histopatolojik yönden herhangi bir patolojik bulgu gözlenmezken, serum ALP, ALT ve indirekt bilirubin değerlerinin kontrol grubundan farksız, karboplatin grubundan ise istatistiksel olarak anlamlı derecede düşük olduğu saptandı. Karboplatinle birlikte C vitamini, E vitamini veya PTX verilmesinin karaciğer hasarına karşı koruyucu etkili olabileceği sonucuna varıldı.

Anahtar Kelimeler:

Karboplatin, Sıçanlar, Pentoksifilin, Vitamin E, Askorbik asit, İlaç toksisitesi

The effect of pentoxifiline, vitamin C and vitamin E on the organ toxicity of carboplatin

In this study, the protective effects of pentoxifylline (PTX), vitamin C and vitamin E on carboplatin toxicity were comparatively investigated in different organs and tissues in rats. Thirty adult rats were divided into 5 groups (n=6), each comprising six animals and the groups were treated daily for five days, by i.p. injections of O, 2 mL saline (Group I), 25 mg/kg carboplatin (Group II), 25 mg/kg carboplatin + 150mg/kg pentoxifylline (Group III), 25 mg/kg carboplatin + 50 mg/kg vitamin C (Group IV) and 25 mg/kg carboplatin + 50 mg/kg vitamin E (Group V). At the end of the treatment, blood samples were collected by direct cardiac puncture and serum was used for the assay of marker enzymes, alanine amino-transferase (ALT), alkaline phosphatase (ALP), direct and indirect bilirubin. Tissue samples were taken and processed by standard histological techniques. At the end of the study, while there were no pathological alterations in the carboplatin group, ALT and ALP activities were significantly increased compared to the control group. There were also no pathological signs in the pentoxifylline, vitamin C and vitamin E groups and ALT, ALP and indirect bilirubin levels were not different from control, but significantly lower than carboplatin groups. These results indicate that the combination of carboplatin with the vitamin C, vitamin E or pentoxifylline may protect against hepatotoxicity.

Keywords:

Carboplatin, Rats, Pentoxifylline, Vitamin E, Ascorbic Acid, Drug Toxicity,

PDF

___

1. Salmon SE, Sartorelli AC. Cancer Chemotherapy. Katzung BG, ed. Basic&Clinical Pharmacology. 8th edition. The McGraw-HİII Companies: 2001: 923
2. Kayaalp SO: Rasyonel tedavi Yönünden Tıbbi Farmakoloji. 9'uncu baskı. Ankara: Hacettepe TAŞ, 2000: 397.
3. Carles J, Nogue M, Domenech M et al. Carboplatin-gemcitabine treatment of patients with transitionai celi carcinoma of the biadder and impaired renal funotion. Oncology 2000; Jun;59(1): 24-27.
4. Chang AY, Hui L, Asbury R et al. Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer. Cancer Chemother Pharmacol 1999; 44 Suppl:S26-28.
5. Shi TZ, Yan JL. Therapeutic effect of carboplatin and etoposide combinative therapy on 123 lung cancer cases. Zhonghua Zhong Liu Za Zhi 1994; Sep;16 (5): 384-386.
6. Holland HK, Dix SP, Geller RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive çare. J Clin Oncol 1996; Apr;14 (4): 1156-1164.
7. Ghalie R, VVilliams SF, Valentino LA et al. Tandem peripheral blood progenitor celi transplants as initial therapy for metastatic breast cancer. Biol Blood Marrovv Transpiant 1995; Nov;1 (1): 40-46.
8. Jones RB, Shpall EJ, Ross M et al. High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrovv support: excessive hepatic toxicity. Cancer Chemother Pharmacol 1990; 26 (2): 155-156.
9. Demirer T, İlhan O, Mandel NM et al. A phase I dose escalation study of high-dose thiotepa, meiphalan and carboplatin (TMCb) follovved by autologous peripheral blood stem celi transplantation (PBSCT) in patients with solid tumors and hematologic maiignancles. Bone Marrovv Transpiant 2000; Apr;25 (7): 697-703.
10. VVelborn JL, Kopecky KJ, Meyers FJ et ai. Carbopiatin infusion in relapsed and refractory acute myeloid leukemia—a Southvvest Oncology Group trial. Leukemia 1995; Jui; 9 (7): 1126-1129.
11. Chu G, Mantin R, Shen YM et al. Massive cisplatin overdose by accidental substitution for carboplatin. Toxicity and management. Cancer 1993; Dec 15; 72 (12): 3707-3714.
12. Ettinger LJ, Krailo MD, Gaynon P al. A phase I study of carboplatin in children with acute leukemia in bone marrovv relapse. A reportfrom the Childrens Cancer Group. Cancer 1993; Aug 1; 72 (3): 917-922.
13. VViedemann GJ, d'Oleire F, Knop E et al. Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. Cancer Res 1994; Oct 15; 54 (20): 5346-5350.
14. Bacha DM, Caparros-Sison B, Ailen JA et al. Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep 1986; Jul; 70 (7): 865-869.
15. Ettinger LJ, Ivy P, Gaynon PS et al. A phase II study of carboplatin as a treatment for children with acute leukemia recurring in bone marrovv: a report of the Children's Cancer Group. Cancer 1986; Jul 15; 80 (2): 311-316.
16. Welborn JL, Kopecky KJ, Meyers FJ et al. Carboplatin infusion in relapsed and refractory acute myeloid leukemia-a Southvvest Oncology Group trial. Leukemia 1995; Jul; 9 (7): 1126-1129.
17. Koçdor MA. Pentoxifyllinin intestinal obstruksiyonda bakteriye! translokasyona etkisi, Uzmanlık Tezi, İzmir, 1995.
18. Samlaska CP, VVinfield AE. Pentoxifylline. J Am Acad Dermatol 1994; 30 (4): 603-621.
19. Shukla VK, Ojha AK, Pandey M et al. Pentoxifylline in perforated peritonitis: results of a randomised, placebo controlled triai. Eur J Surg 2001; 167 (8): 622-624.
20. Sneed RA, Buchvveitz JP, Jean PA, Ganey PE. Pentoxifylline attenuates bacterial lipopolysaccharide-induced enhancement of aliyi alcohol hepatotoxicity. Toxicol Sci. 2000; Jul; 56 (1): 203-210.
21. Helen A, Krishnakumar K, Vijayammal PL, Augusti KT. Antioxidant effect of onion oil {Allium cepa. Linn) on the damages induced by nicotine in rats as compared to alpha-tocopherol. Toxicol Lett. 2000; 116:61-68.
22. Slater TF. Free radical mechanisms in tissue injury. Biochem J. 1984; 222: 1-15.
23. Yao T, Esposti SD, Huang L, Arnon R, Spangenberger A, and Zern MA. Inhibition of carbon tetrachloride-induced liver injury by liposomes cotaining vitamin E. Am J Physiol. 1994; 267 (gastrointest. liver physiol. 30): g476-g484.
24. Parola M, Leonarduzzi G, Biasi F, Albano E, Biocca ME, Poli G, and Dianzani M. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis. Hepatology. 1992; 16:1014-1021.
25. Sinclair AJ, Barnet AH, Lunec J. Free radicals and antioxidant systems in health and disease. Br J Hosp Med. 1990; 43:334-344.
26. Teicher BA, Holden SA, Herman TS, Epelbaum R, Pardee AB, Dezube B. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res 1991; Jul-Aug;11 (4): 1555-1560.
27. Meier-Bratschi A, Lutz WK, Schlatter C. Methylation of liver DNA of rat and mouse by N-nitrosodimethylamine formed in vivo from dimethylamine and nitrite. Food Chem Toxicol 1983; Jun; 21 (3): 285-289.
28. Koleva M, Donchev N, Borov B, Dzharova V. Experimental research on the toxicity of pharmapentoxifyllirıe (II). Eksp Med Morfol 1990; 29 (4): 57-61.
29. Hayran M, Özdemir O. Bilgisayar İstatistik ve Tıp. Ankara: Medikomat, 1995. 30. Özdamar K. SPSS ile Bivoistatistik. 4'üncü baskı. Eskişehir: Kaan Kitabevi, 2001.
31. Kayaalp SO: Rasyonel tedavi Yönünden Tıbbi Farmakoloji. 10'uncu baskı. Ankara: Hacettepe TAŞ, 2002: 471.